Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival
The immune checkpoint inhibitor ipilimumab provides long term survival in some metastatic melanoma patients, but the majority has no benefit, and may experience serious side effects. Here, we investigated the dynamics of plasma cytokine concentrations and their potential utility for predicting treat...
Saved in:
| Main Authors: | Ragnhild Reehorst Lereim, Claire Dunn, Elin Aamdal, Sudhir Kumar Chauhan, Oddbjørn Straume, Tormod Kyrre Guren, Jon Amund Kyte |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2024.2440967 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Neoadjuvant immunotherapy with ipilimumab/nivolumab induces a complete response of a primary malignant melanoma in an 89 years old patient
by: Pascal Spahn, et al.
Published: (2024-12-01) -
Combatting mucosal melanoma: recent advances and future perspectives
by: Helen Tyrrell, et al.
Published: (2018-09-01) -
RECIST 1.1 AND irRC FOR RESPONSE ASSESMENT IN PATIENTS WITH DISSEMINATED CUTANEOUS MELANOMA TREATED WITH IPILIMUMAB OR DENDRITIC CELL VACCINE
by: A. V. Novik, et al.
Published: (2019-09-01) -
Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment
by: Sabine Schmid, MD, et al.
Published: (2024-12-01) -
Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma
by: Valerie Glutsch, et al.
Published: (2024-12-01)